Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT

Geode Capital Management LLC lifted its stake in Altimmune, Inc. (NASDAQ:ALT) by 13.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,934,880 shares of the company’s stock after purchasing an additional 228,995 shares during the quarter. Geode Capital Management LLC owned about 2.39% of Altimmune worth $7,489,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Kingswood Wealth Advisors LLC purchased a new stake in Altimmune during the 2nd quarter worth approximately $40,000. Geneos Wealth Management Inc. acquired a new stake in shares of Altimmune during the first quarter worth $50,000. Los Angeles Capital Management LLC purchased a new stake in shares of Altimmune during the second quarter valued at $54,000. Keudell Morrison Wealth Management acquired a new position in shares of Altimmune in the 2nd quarter valued at $63,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Altimmune by 20.3% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock valued at $67,000 after acquiring an additional 2,268 shares during the period. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have commented on ALT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Altimmune in a research report on Monday. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. B. Riley decreased their target price on Altimmune from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. UBS Group dropped their target price on Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Finally, Citizens Jmp reduced their price target on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and a consensus price target of $16.83.

Altimmune Stock Down 1.3%

Shares of ALT opened at $5.24 on Friday. The company has a market capitalization of $546.74 million, a price-to-earnings ratio of -4.90 and a beta of -0.03. Altimmune, Inc. has a 52 week low of $2.90 and a 52 week high of $9.95. The stock’s 50-day moving average price is $4.27 and its 200-day moving average price is $4.44. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%.The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. On average, sell-side analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.